文献速递肝病消化道肿瘤与早癌消化内镜

胆汁甲基化标志物可早期准确检测原发性硬化性胆管炎相关胆管癌

Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
PubMed 文献 · Hepatology · 2021-12-05

本研究采用微滴数字PCR检测273例患者344份胆汁样本中四个基因的启动子甲基化,用于原发性硬化性胆管炎(PSC)相关胆管癌(CCA)的检测。在胆汁采集后≤12个月内诊断为CCA的PSC患者中,联合检测灵敏度达100%(28/28),特异度90%(20/203),且在长期随访对照中特异度达93%。

要点

  • 胆汁甲基化标志物联合检测可在CCA诊断前12个月内准确识别PSC相关CCA。
  • 在PSC患者中检测CCA的AUC为0.77-0.87,联合检测灵敏度100%、特异度90%。
  • 标志物阳性不受肿瘤分期、生长模式、解剖位置及CA19-9水平影响。

核心结论

  • 采用高灵敏度ddPCR检测胆汁表观遗传标志物,可在CCA诊断前12个月内准确检测PSC相关CCA,且不受临床和分子特征影响。

研究设计与样本

  • 使用微滴数字PCR分析273例散发性及PSC相关CCA、PSC和其他非恶性肝病患者的344份胆汁样本中四个基因的启动子甲基化。

主要发现

  • ROC曲线分析显示四个标志物在PSC患者中检测CCA的AUC为0.77-0.87。
  • 仅纳入胆汁采集后≤12个月内诊断为CCA的PSC患者样本时,联合灵敏度为100%(28/28),特异度为90%(20/203)。
  • 仅纳入长期随访(>36个月)的PSC患者作为对照时,特异度提高至93%。
  • 仅纳入伴有不典型增生(dysplasia)的PSC患者作为对照(n=23)时,特异度仍高达83%。
  • CCA-PSC≤12患者中所有标志物阳性的胆汁样本涵盖了早期和晚期CCA、不同肿瘤生长模式、解剖位置及CA19-9水平。

关键数值与推荐

  • 在PSC患者中检测CCA,四个甲基化标志物的AUC范围为0.77-0.87。
  • 在胆汁采集后≤12个月内诊断CCA的PSC患者中,联合检测灵敏度为100%(28/28),特异度为90%(20/203)。
  • 以长期随访(>36个月)PSC患者为对照时,特异度为93%。
  • 以伴有不典型增生的PSC患者(n=23)为对照时,特异度为83%。

临床怎么用

  • 对于PSC患者,胆汁甲基化标志物检测可能有助于早期发现CCA,补充现有检测和筛查方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is associated with increased risk of cholangiocarcinoma (CCA). Early and accurate CCA detection represents an unmet clinical need as the majority of patients with PSC are diagnosed at an advanced stage of malignancy. In the present study, we aimed at establishing robust DNA methylation biomarkers in bile for early and accurate diagnosis of CCA in PSC. APPROACH AND RESULTS: Droplet digital PCR (ddPCR) was used to analyze 344 bile samples from 273 patients with sporadic and PSC-associated CCA, PSC, and other nonmalignant liver diseases for promoter methylation of cysteine dioxygenase type 1, cannabinoid receptor interacting protein 1, septin 9, and vimentin. Receiver operating characteristic (ROC) curve analyses revealed high AUCs for all four markers (0.77-0.87) for CCA detection among patients with PSC. Including only samples from patients with PSC diagnosed with CCA ≤ 12 months following bile collection increased the accuracy for cancer detection, with a combined sensitivity of 100% (28/28) and a specificity of 90% (20/203). The specificity increased to 93% when only including patients with PSC with longtime follow-up (> 36 months) as controls, and remained high (83%) when only including patients with PSC and dysplasia as controls (n = 23). Importantly, the bile samples from the CCA-PSC ≤ 12 patients, all positive for the biomarkers, included both early-stage and late-stage CCA, different tumor growth patterns, anatomical locations, and carbohydrate antigen 19-9 levels. CONCLUSIONS: Using highly sensitive ddPCR to analyze robust epigenetic biomarkers, CCA in PSC was accurately detected in bile, irrespective of clinical and molecular features, up to 12 months before CCA diagnosis. The findings suggest a potential for these biomarkers to complement current detection and screening methods for CCA in patients with PSC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vedeld HM, Grimsrud MM, Andresen K, et al. Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. Hepatology. 2021. PMID: 34435693. doi:10.1002/hep.32125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。